Apr 11 2012
Vilex Inc., a leader in innovative orthopaedic medical devices announced the commercial launch of the FUZE™ TTC Arthrodesis Compression Nail, the most recent addition to the Vilex line. The device is currently patent pending and has received 510(k) clearance from the FDA. The Vilex FUZE™ provides unparalleled compression in ankle fusion for trauma, diabetic Charcot foot reconstruction, and patients with arthritis. The FUZE™ combines the compression capability of a screw and the structural strength of intramedullary nail fixation in one device.
The FUZE™ was developed in collaboration with board certified orthopaedic foot and ankle specialist Dr. Steven Neufeld, M.D., and designed to be minimally invasive with both patients and surgeons in mind. The cannulation assures a proper positioning of the implant within the intramedullary canal. The main features of the design are the three thread segments and the six locking cross screws. A precise targeting device assists the surgeon in engaging cross-screws without direct visualization.
The FUZE™ is threaded at the leading end, middle, and head to provide both ankle joint compression and load support. The leading thread and its synchronized pitch serves as drill and a tap for the middle thread segment. The head features a cortical thread intended to engage the plantar aspect of the calcaneus. The middle thread is designed to engage the distal tibia without crossing the ankle joint. The FUZE™ achieves additional compression, up to 9 mm, across the ankle joint by virtue of the pitch differential between the head and middle threads.
There are two locking screws near the head, both oriented lateral-medial, and one inclined 45o anterior-posterior to compress the calcaneus to the talus. Proximally there are three locking screws: two are lateral-medial and one anterior-posterior. The FUZE™ is offered in either titanium or stainless steel in five thread diameters from 10-14mm and lengths 150mm-300mm. The 5.0mm locking screws are fully threaded.